Cybin (NYSE American: CYBN) (NEO: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options. The company today announced that the U.S. Patent and Trademark Office (“USPTO”) has granted U.S. patent 11,724,985 to a deuterated psilocybin analog in Cybin’s CYB003 investigational drug program. “We are … Continue reading InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Secures New US Patent Supporting Its CYB003 Program